DE69736806D1 - ErbB3 ANTIKÖRPER - Google Patents

ErbB3 ANTIKÖRPER

Info

Publication number
DE69736806D1
DE69736806D1 DE69736806T DE69736806T DE69736806D1 DE 69736806 D1 DE69736806 D1 DE 69736806D1 DE 69736806 T DE69736806 T DE 69736806T DE 69736806 T DE69736806 T DE 69736806T DE 69736806 D1 DE69736806 D1 DE 69736806D1
Authority
DE
Germany
Prior art keywords
erbb3
erbb2
heregulin
ability
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69736806T
Other languages
English (en)
Other versions
DE69736806T3 (de
DE69736806T2 (de
Inventor
Robert Akita
Mark Sliwkowski
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24500380&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69736806(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of DE69736806D1 publication Critical patent/DE69736806D1/de
Application granted granted Critical
Publication of DE69736806T2 publication Critical patent/DE69736806T2/de
Publication of DE69736806T3 publication Critical patent/DE69736806T3/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Apparatus For Radiation Diagnosis (AREA)
  • Investigating Or Analysing Materials By Optical Means (AREA)
DE69736806.8T 1996-03-27 1997-03-07 ErbB3 ANTIKÖRPER Expired - Lifetime DE69736806T3 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US62403696A 1996-03-27 1996-03-27
US624036 1996-03-27
PCT/US1997/003546 WO1997035885A1 (en) 1996-03-27 1997-03-07 ErbB3 ANTIBODIES
EP97908923.2A EP0896586B2 (de) 1996-03-27 1997-03-07 ErbB3 ANTIKÖRPER

Publications (3)

Publication Number Publication Date
DE69736806D1 true DE69736806D1 (de) 2006-11-23
DE69736806T2 DE69736806T2 (de) 2007-08-09
DE69736806T3 DE69736806T3 (de) 2015-10-08

Family

ID=24500380

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69736806.8T Expired - Lifetime DE69736806T3 (de) 1996-03-27 1997-03-07 ErbB3 ANTIKÖRPER

Country Status (15)

Country Link
EP (2) EP0896586B2 (de)
JP (1) JP3925943B2 (de)
CN (1) CN1214044C (de)
AT (1) ATE342283T1 (de)
AU (1) AU727082B2 (de)
BR (1) BR9708343A (de)
CA (1) CA2246429C (de)
DE (1) DE69736806T3 (de)
DK (1) DK0896586T4 (de)
ES (1) ES2274537T5 (de)
IL (2) IL126303A0 (de)
NZ (1) NZ331360A (de)
PT (1) PT896586E (de)
WO (1) WO1997035885A1 (de)
ZA (1) ZA972554B (de)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6417168B1 (en) 1998-03-04 2002-07-09 The Trustees Of The University Of Pennsylvania Compositions and methods of treating tumors
AUPQ105799A0 (en) * 1999-06-18 1999-07-08 Victor Chang Cardiac Research Institute, The Cell growth inhibition
PL202369B1 (pl) 1999-08-27 2009-06-30 Genentech Inc Zastosowanie przeciwciała skierowanego przeciw ErbB2, zastosowanie przeciwciała skierowanego przeciw ErbB oraz zestaw zawierający to przeciwciało
EP1283053A1 (de) * 2001-08-09 2003-02-12 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Inhibitore der HER3 Aktivität
AU2008200654B2 (en) * 2001-08-09 2010-04-29 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Inhibitors of HER3 activity
EP1495123B1 (de) 2002-03-26 2013-10-30 Zensun (Shanghai) Science and Technology Limited Auf erbb3 beruhende verfahren und zusammensetzungen zur behandlung von neoplasmen
JP5069843B2 (ja) 2002-07-15 2012-11-07 ジェネンテック， インコーポレイテッド 抗ＥｒｂＢ２抗体を用いる処置に応答性である腫瘍を同定するための方法
BRPI0510883B8 (pt) 2004-06-01 2021-05-25 Genentech Inc composto conjugado de droga e anticorpo, composição farmacêutica, método de fabricação de composto conjugado de droga e anticorpo e usos de uma formulação, de um conjugado de droga e anticorpo e um agente quimioterapêutico e de uma combinação
PL1791565T3 (pl) 2004-09-23 2016-10-31 Modyfikowane cysteiną przeciwciała i koniugaty
US20100111856A1 (en) 2004-09-23 2010-05-06 Herman Gill Zirconium-radiolabeled, cysteine engineered antibody conjugates
AR056857A1 (es) 2005-12-30 2007-10-24 U3 Pharma Ag Anticuerpos dirigidos hacia her-3 (receptor del factor de crecimiento epidérmico humano-3) y sus usos
EP2518508A1 (de) 2006-11-28 2012-10-31 U3 Pharma GmbH Aktiviertes HER3 als Marker zur Vorhersage der Therapieeffizienz
PL2129396T3 (pl) 2007-02-16 2014-02-28 Merrimack Pharmaceuticals Inc Przeciwciała przeciw ERBB3 i ich zastosowania
EA022884B1 (ru) * 2008-08-15 2016-03-31 Мерримак Фармасьютикалз, Инк. СПОСОБ ЛЕЧЕНИЯ ЗЛОКАЧЕСТВЕННОЙ ОПУХОЛИ С ИСПОЛЬЗОВАНИЕМ АНТИ-ErbB3 АНТИТЕЛА
WO2010115552A1 (en) 2009-04-07 2010-10-14 Roche Glycart Ag Bispecific anti-erbb-3/anti-c-met antibodies
DK3351558T3 (da) 2009-11-13 2020-06-02 Daiichi Sankyo Europe Gmbh Materiale og fremgangsmåder til behandling eller forebyggelse af her-3-relaterede sygdomme
EP3778917A3 (de) 2009-12-04 2021-06-09 F. Hoffmann-La Roche AG Multispezifische antikörper, antikörperanaloge, zusammensetzungen und verfahren
US8859737B2 (en) 2009-12-22 2014-10-14 Roche Glycart Ag Anti-HER3 antibodies and uses thereof
PT2544680E (pt) 2010-03-11 2015-05-06 Merrimack Pharmaceuticals Inc Uso de inibidores de erbb3 no tratamento de cancro da mama triplo negativo
WO2011136911A2 (en) * 2010-04-09 2011-11-03 Aveo Pharmaceuticals, Inc. Anti-erbb3 antibodies
NZ604003A (en) 2010-05-27 2015-04-24 Genmab As Monoclonal antibodies against her2
CN103153339B (zh) 2010-05-27 2021-05-04 根马布股份公司 针对her2表位的单克隆抗体
CA2803900A1 (en) 2010-07-09 2012-01-12 Exelixis, Inc. Combinations of kinase inhibitors for the treatment of cancer
TW201302793A (zh) 2010-09-03 2013-01-16 Glaxo Group Ltd 新穎之抗原結合蛋白
ES2616961T3 (es) * 2010-11-01 2017-06-14 Symphogen A/S Composición de anticuerpos pan-HER
JP5588086B2 (ja) 2011-04-19 2014-09-10 メリマック ファーマシューティカルズ インコーポレーティッド 単一特異性および二重特異性抗ＩＧＦ‐１Ｒ抗体および抗ＥｒｂＢ３抗体
US20140170149A1 (en) 2011-04-20 2014-06-19 Genmab A/S Bispecific antibodies against her2 and cd3
US9273143B2 (en) 2011-09-30 2016-03-01 Regeneron Pharmaceuticals, Inc. Methods and compositions comprising a combination of an anti-ErbB3 antibody and an anti-EGFR antibody
EA201791393A3 (ru) 2011-09-30 2018-03-30 Ридженерон Фармасьютикалз, Инк. Антитела к erbb3 и их применение
CN103959065B (zh) 2011-10-06 2018-07-17 Aveo制药公司 预测肿瘤对抗erbb3抗体的应答
WO2013053076A1 (en) 2011-10-10 2013-04-18 Zensun （Shanghai）Science & Technology Limited Compositions and methods for treating heart failure
JP6149042B2 (ja) * 2011-11-09 2017-06-14 ザ ユーエービー リサーチ ファンデーション Ｈｅｒ３抗体およびその使用
EP2797957B1 (de) * 2011-11-23 2019-06-19 MedImmune, LLC Her3-spezifische bindungsmoleküle und verwendungen davon
ES2758433T3 (es) * 2011-12-05 2020-05-05 Novartis Ag Anticuerpos contra el receptor 3 del factor de crecimiento epidérmico (HER3)
EA201500503A1 (ru) * 2012-11-08 2015-10-30 Ф.Хоффманн-Ля Рош Аг Анти-her3/her4 антигенсвязывающие белки, связывающиеся с бета-шпилькой her3 и бета-шпилькой her4
MA38165A1 (fr) 2012-11-08 2018-07-31 Hoffmann La Roche Protéines de liaison à l'antigène her3 se liant à l'épingle à cheveux beta de her3
US9180185B2 (en) 2013-01-11 2015-11-10 Hoffman-La Roche Inc. Combination therapy of anti-HER3 antibodies
WO2015048008A2 (en) 2013-09-24 2015-04-02 Medimmune, Llc Binding molecules specific for her3 and uses thereof
WO2015100459A2 (en) 2013-12-27 2015-07-02 Merrimack Pharmaceuticals, Inc. Biomarker profiles for predicting outcomes of cancer therapy with erbb3 inhibitors and/or chemotherapies
WO2015157634A1 (en) 2014-04-11 2015-10-15 Kolltan Pharmaceuticals, Inc. Anti-erbb antibodies and methods of use thereof
CN106459207B (zh) 2014-05-14 2020-07-10 豪夫迈·罗氏有限公司 结合HER3β-发夹的抗HER3抗体
US10184006B2 (en) 2015-06-04 2019-01-22 Merrimack Pharmaceuticals, Inc. Biomarkers for predicting outcomes of cancer therapy with ErbB3 inhibitors
WO2022078490A1 (zh) * 2020-10-15 2022-04-21 上海翰森生物医药科技有限公司 抗erbb3抗体或其抗原结合片段及其医药用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5183884A (en) * 1989-12-01 1993-02-02 United States Of America Dna segment encoding a gene for a receptor related to the epidermal growth factor receptor
AU662311B2 (en) * 1991-02-05 1995-08-31 Novartis Ag Recombinant antibodies specific for a growth factor receptor
WO1993016185A2 (en) * 1992-02-06 1993-08-19 Creative Biomolecules, Inc. Biosynthetic binding protein for cancer marker
AU4025193A (en) * 1992-04-08 1993-11-18 Cetus Oncology Corporation Humanized C-erbB-2 specific antibodies
WO1994022478A1 (en) * 1993-03-30 1994-10-13 The Trustees Of The University Of Pennsylvania PREVENTION OF TUMORS WITH MONOCLONAL ANTIBODIES AGAINST $i(NEU)
US5783186A (en) * 1995-12-05 1998-07-21 Amgen Inc. Antibody-induced apoptosis

Also Published As

Publication number Publication date
ZA972554B (en) 1998-09-25
EP1728802A2 (de) 2006-12-06
CA2246429C (en) 2007-07-24
DK0896586T3 (da) 2007-02-19
JP3925943B2 (ja) 2007-06-06
CA2246429A1 (en) 1997-10-02
EP0896586B2 (de) 2015-05-20
DE69736806T3 (de) 2015-10-08
EP0896586B1 (de) 2006-10-11
CN1214044C (zh) 2005-08-10
DK0896586T4 (en) 2015-08-24
IL126303A (en) 2002-05-23
ES2274537T5 (es) 2015-09-14
PT896586E (pt) 2007-01-31
BR9708343A (pt) 1999-08-03
JP2000508526A (ja) 2000-07-11
ES2274537T3 (es) 2007-05-16
EP1728802A3 (de) 2006-12-13
ATE342283T1 (de) 2006-11-15
IL126303A0 (en) 1999-05-09
CN1214695A (zh) 1999-04-21
AU727082B2 (en) 2000-11-30
DE69736806T2 (de) 2007-08-09
NZ331360A (en) 2000-03-27
AU2071197A (en) 1997-10-17
EP0896586A1 (de) 1999-02-17
WO1997035885A1 (en) 1997-10-02

Similar Documents

Publication Publication Date Title
DE69736806D1 (de) ErbB3 ANTIKÖRPER
EP1071460A4 (de) Internalisierende erb2 antikörper
EP0930366A3 (de) Bindungsdomänen des Serrate-proteins
PT1135498E (pt) Variantes de anticorpos com maior afinidade de ligação em comparação com os anticorpos parentais
EP0942959A4 (de) Transgene nicht-menschliche tiere, die heterologe antikörper erzeugen können
CY1110877T1 (el) Αλλαγη των συγγενειων συνδεσης me fcrn ή των ημιζωων ορου αντισωματων με μεταλλαξιγενεση
ATE213837T1 (de) Polypeptid-dendrimer komplexe
WO2001040307A8 (de) Antikörper gegen signal-regulator-proteine
ES2106195T3 (es) Anticuerpo igg aglicosilado anti cd3.
EP0728215A4 (de) METHODE ZUR BINDUNG VON MATERIAL AN DAS -g(b)-AMYLOID-PEPTID
FI961285A (fi) CD40:n vasta-aineita
IL154000A (en) A method that uses antibodies to diagnose arthritis
WO1996027665A3 (en) Neuron-restrictive silencer factor proteins
ATE217086T1 (de) Herstellung von photoprotein konjugaten und verfahren zu ihrer verwendung
NZ336781A (en) Fibronectin binding protein compositions, antibodies thereto, and methods of use
CA2589421A1 (en) Erbb3 antibodies
AU2001255398A1 (en) Surface-bound antigen binding portions of antibodies that bind to ctla-4 and cd28 and uses therefor
AU2726388A (en) Determination method, use and components
WO1999024835A3 (en) An immunoassay for procollagen-iii-c-terminal propeptide
DE59310280D1 (de) Verfahren zur Herstellung von Konjugaten aus einem spezifischen Bindungspartner und einem kohlenhydrathaltigen Protein
WO2002076406A3 (en) Antibodies against autoantigens of primary biliary cirrhosis and methods of making and using them
DE69220863T2 (de) Denaturierte transportproteine zur verbesserung von enzymgebundenen immunoassays (elisa)
EP1950300A3 (de) Antikörpervarianten mit höherer Bindungsaffinität im Vergleich zu verwandten Antikörpern
GB2333295A (en) Modified protein G and fragments thereof
AU1595901A (en) Antibodies to suberic acid crosslinkers and methods for using the same

Legal Events

Date Code Title Description
8363 Opposition against the patent